Quantum BioPharma Ltd.
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. It operates through two segments, Biopharmaceutical Innovation and Strategic Investments. The company researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in d… Read more
Quantum BioPharma Ltd. (QNTM) - Total Liabilities
Latest total liabilities as of September 2025: $6.65 Million USD
Based on the latest financial reports, Quantum BioPharma Ltd. (QNTM) has total liabilities worth $6.65 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Quantum BioPharma Ltd. - Total Liabilities Trend (2015–2024)
This chart illustrates how Quantum BioPharma Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Quantum BioPharma Ltd. Competitors by Total Liabilities
The table below lists competitors of Quantum BioPharma Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chai Watana Tannery Group Public Company Limited
BK:CWT
|
Thailand | ฿1.66 Billion |
|
Pelikan International Corp
KLSE:5231
|
Malaysia | RM80.74 Million |
|
Livium Ltd
AU:LIT
|
Australia | AU$13.18 Million |
|
Urano Energy Corp.
OTCQB:UECXF
|
USA | $191.70K |
|
ATA IMS Bhd
KLSE:8176
|
Malaysia | RM169.26 Million |
|
Univastu India Limited
NSE:UNIVASTU
|
India | ₹1.48 Billion |
|
Swvl Holdings Corp
NASDAQ:SWVL
|
USA | $17.53 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Quantum BioPharma Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.77 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Quantum BioPharma Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Quantum BioPharma Ltd. (2015–2024)
The table below shows the annual total liabilities of Quantum BioPharma Ltd. from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $6.68 Million | +46.29% |
| 2023-12-31 | $4.57 Million | -41.98% |
| 2022-12-31 | $7.87 Million | -10.91% |
| 2021-12-31 | $8.83 Million | +56.08% |
| 2020-12-31 | $5.66 Million | -18.47% |
| 2019-12-31 | $6.94 Million | +442.08% |
| 2018-12-31 | $1.28 Million | +27.17% |
| 2017-12-31 | $1.01 Million | +1538.76% |
| 2016-12-31 | $61.43K | +1.49% |
| 2015-12-31 | $60.53K | -- |